Calliditas Confident Of Keeping Ahead Of Travere In IgAN
Hoping For Up To $150m Sales This Year
Executive Summary
The Swedish group’s Tarpeyo is reaping the benefits of an expanded US sales force and the company is confident of a big revenue rise in 2023, regardless of new competition in the IgAN field from Travere’s Filspari.
You may also be interested in...
Deal Watch: Sangamo Inks Significant Option Deal With Prevail After Losing Tie-Ups With Novartis, Biogen
Plus deals involving Novartis/DTx, Neurogene/Neoleukin, Travere/Mirum, Sanofi/Scribe, Korro Bio/Frequency, MaxCyte/viTToria and more.
Calliditas Spies Chinese Market As Tarpeyo Continues Upwards Sales Curve
The Swedish biotech’s successful launch in the US of Tarpeyo for immunoglobulin A nephropathy is progressing well and a Chinese approval is on the horizon as partner Everest’s application is accepted by regulators.
Stada Poised To Launch As Calliditas Finally Wins EU Nod For Kinpeygo
The Swedish biotech’s patience paid off as it received a positive EU CHMP opinion on its rare nephrology drug Kinpeygo, known elsewhere as Tarpeyo, following delays related to manufacturing questions.